You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Newborn Infant Vision Test

    SBC: Precision Vision, Inc.            Topic: N

    Project Summary! This STTR Phase II project continues the development of the Newborn Acuity Cardstm and the Newborn Contrast Cardstm Together these Newborn Cards form a new clinical test of visual acuity and contrast sensi tivity for use on newborn full term and preterm infants The stimuli are square wave gratings which the examiner presents to the infant in a fixation and following protocol ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Compact Laser Drivers for Photoconductive Semiconductor Switches

    SBC: ASR Corporation            Topic: DTRA16A004

    A compact laser driver will allow photoconductive semiconductor switches to be used in small EMP simulator "building blocks" (EMPBB). Combined with a battery powered on-board pulsed power system, these EMPBBs will allow the construction of flexible EMP test facilities with nothing more than a single fiber optic timing connection to each EMPBB.

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A mobile app to reduce treatment-related financial burden for cancer patients

    SBC: Vivor, Llc            Topic: NCI

    There is a fundamental knowledge gap in how to immediately reduce cancer patientsandapos treatment related financial burden Cancer patients pay more out of pocket for their care than those with other chronic illnesses Half of all elderly cancer patients have high treatment related out of pocket financial burden This financial burden has well defined harmful effects even among insured cancer pa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Caduceus Quest: A serious STEM game to promote reproductive health and STEM and health career interest

    SBC: RESILIENT GAMES STUDIO, LLC            Topic: OD

    DESCRIPTION provided by applicant The proposed Phase I STTR project will develop and test a serious game Caduceus Quest to engage youth in STEM learning facilitate reductions in sexual and reproductive health risk behaviors and promote asset development toward holistic long term well being Caduceus Quest will be a multi platform theory based role playing game in which players build up t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Developing an Affordable and Pocketable POC Device for Monitoring Lithium and Sodium in Patients with Bipolar Disorder

    SBC: GLUCOSENTIENT INC            Topic: 102

    Project Summary Abstract The objective of this Phase I STTR project is to demonstrate feasibility of developing a selective affordable and pocket sized device to enable regular and quantitative monitoring of both Li and Na levels in the blood of patients with bipolar disorder BD which is one of the most common mental illnesses affecting over million Americans costing the healthcare syst ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Screening the Ribosome for New Target Sites

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government